BioXcel director granted options on 17,000 shares

BioXcel Therapeutics, Inc. reported that director Susan E. Atkins received a grant of stock options for 17,000 shares of common stock on August 12, 2026.

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. reported that director Susan E. Atkins received a grant of stock options for 17,000 shares of common stock on August 12, 2026. The options carry an exercise price of $1.06 per share and expire on August 12, 2036. One-third of the options vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal annual installments on the second and third anniversaries, contingent on her continued service with the company.

Insider Trade Summary

Grant/Award: 17,000 shares

Grant/Award 1 txn

Insider Atkins Susan E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	17,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates.

Key Figures

Options granted: 17,000 shares Exercise price: $1.06 per share Underlying shares: 17,000 shares +2 more

5 metrics

Options granted 17,000 shares Stock option grant to director Susan E. Atkins on August 12, 2026

Exercise price $1.06 per share Conversion or exercise price of stock options granted

Underlying shares 17,000 shares Common stock underlying the stock option award

Post-grant derivative holdings 17,000 options Total derivative securities held following the reported transaction

Option expiration August 12, 2036 Expiration date of the stock options granted to the director

Key Terms

Stock Option (Right to Buy), underlying shares, vesting

3 terms

Stock Option (Right to Buy) financial

"Security title reported as "Stock Option (Right to Buy)""

underlying shares financial

"The option vests and becomes exercisable as to 33% of the underlying shares"

vesting financial

"The option vests and becomes exercisable as to 33% of the underlying shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioXcel Therapeutics (BTAI) disclose about Susan E. Atkins in this Form 4?

BioXcel Therapeutics disclosed that director Susan E. Atkins received a stock option grant for 17,000 shares on August 12, 2026, with an exercise price of $1.06 per share and an expiration date of August 12, 2036.

What is the vesting schedule for Susan E. Atkins’s new options at BTAI?

The options vest as to 33% of the 17,000 shares on the first anniversary of the August 12, 2026 grant date. The remaining shares vest in two equal annual installments on the second and third anniversaries, subject to her continuous service.

What is the exercise price of the stock options granted to Susan E. Atkins at BioXcel Therapeutics (BTAI)?

The stock options granted to Susan E. Atkins have an exercise price of $1.06 per share. They cover 17,000 shares of common stock and were granted on August 12, 2026, expiring on August 12, 2036.

How many BioXcel Therapeutics (BTAI) shares can Susan E. Atkins acquire through this option grant?

The grant allows Susan E. Atkins to acquire up to 17,000 shares of BioXcel Therapeutics common stock upon exercise of the options, which vest over three years and carry a $1.06 exercise price per share.

When do Susan E. Atkins’s BioXcel Therapeutics (BTAI) options expire?

The stock options granted to Susan E. Atkins expire on August 12, 2036. They were granted on August 12, 2026, cover 17,000 underlying shares, and vest over a three-year period subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 07:01 PM Accepted by SEC EDGAR 08/14/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkins Susan E.

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CONNECTICUT 06511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.06	08/12/2026		A		17,000		(1)	08/12/2036	Common Stock	17,000	$0	17,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates.

	/s/ Javier Rodriguez, Attorney-in-Fact for Susan E. Atkins	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)